Bruntwood SciTech has unveiled its £20m lab redevelopment at Alderley Park, Macclesfield, part of a £247m plan to bolster life science innovation in the region and attract more companies to the area.
Alderley Park has seen 86,000 sq ft of its existing labs redeveloped into high-specification biology and chemistry containment level two laboratory suites.
“The life sciences sector is witnessing rapid and continued growth in the North West and the creation of these pioneering workspaces speaks to that demand,” said Kath Mackay, director, life sciences, Bruntwood SciTech.
Bruntwood SciTech is a joint venture between property investor and developer Bruntwood and financial services firm Legal & General.
Bruntwood SciTech said the lab will be for companies working in drug discovery, oncology, infectious diseases and advanced therapy medicinal products.
Out of the £20m, £4m was supplied by the Cheshire and Warrington Local Enterprise Partnership.
The investment comes as part of Bruntwood SciTech’s wider plan to create an additional 200,000 sq ft of lab space and office space for technology businesses.
“Alderley Park is already a world-leading campus for science and technology and a key location for the North’s thriving life sciences sector. Investing in its future will keep this facility – and its businesses – at the forefront of regional, national and international innovation,” added Mackay.
The Macclesfield site was purchased by Bruntwood in 2014 from former occupants AstraZeneca, the pharmaceutical and biotechnology company that developed one of the Covid-19 vaccines.
It homes more than 250 businesses such as Cancer Research UK’s Manchester Institute team.
It’s not the only project that the property developer has on the go. In June it showed off its £21m tech hub at Manchester Science Park, part of a one million sq ft plan.
Bruntwood joined forces with Investment bank GP Bullhound earlier this year to form the angel investment network Manchester Angels.